Snehal Patel Buys 174,825 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSIGet Free Report) CEO Snehal Patel bought 174,825 shares of the company’s stock in a transaction dated Thursday, June 13th. The stock was purchased at an average price of $14.30 per share, for a total transaction of $2,499,997.50. Following the purchase, the chief executive officer now owns 5,525,602 shares of the company’s stock, valued at approximately $79,016,108.60. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Snehal Patel also recently made the following trade(s):

  • On Monday, April 1st, Snehal Patel bought 3,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $19.08 per share, for a total transaction of $57,240.00.
  • On Friday, March 22nd, Snehal Patel bought 2,500 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $19.98 per share, for a total transaction of $49,950.00.
  • On Wednesday, March 20th, Snehal Patel bought 1,500 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $17.68 per share, for a total transaction of $26,520.00.

Greenwich LifeSciences Stock Down 8.4 %

Shares of Greenwich LifeSciences stock opened at $15.97 on Wednesday. The company has a market cap of $205.69 million, a price-to-earnings ratio of -22.18 and a beta of 1.60. The company’s 50 day moving average is $13.95 and its 200 day moving average is $12.99. Greenwich LifeSciences, Inc. has a twelve month low of $7.58 and a twelve month high of $21.44.

Greenwich LifeSciences (NASDAQ:GLSIGet Free Report) last issued its quarterly earnings data on Monday, May 20th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01. Sell-side analysts expect that Greenwich LifeSciences, Inc. will post -0.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Greenwich LifeSciences stock. Vanguard Group Inc. raised its holdings in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSIFree Report) by 0.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 223,102 shares of the company’s stock after buying an additional 1,420 shares during the period. Vanguard Group Inc. owned about 1.73% of Greenwich LifeSciences worth $4,449,000 at the end of the most recent quarter. 4.16% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $36.00 price objective on shares of Greenwich LifeSciences in a research report on Wednesday, May 22nd.

Get Our Latest Research Report on Greenwich LifeSciences

Greenwich LifeSciences Company Profile

(Get Free Report)

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

Featured Stories

Insider Buying and Selling by Quarter for Greenwich LifeSciences (NASDAQ:GLSI)

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.